Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2024-11-12 Regulatory Filings
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2024-11-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notification from Windlas Biotech Limited about a scheduled conference call to discuss the financial performance for the quarter ended September 30, 2024. It references the SEBI Listing Obligations and Disclosure Requirements Regulations, indicating a regulatory compliance announcement. The document includes details about the date, time, and participation instructions for the call but does not contain any financial data or results itself. It is an announcement of an upcoming conference call, not the transcript or the financial report. Therefore, the document fits the category of a Call Transcript announcement or invitation, but since it is only scheduling the call and inviting participants, it is best classified as a Call Transcript (CT) related document. Given the content, the classification is CT with high confidence.
2024-11-05 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2024-11-05 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2024. It is a formal announcement to stock exchanges about the upcoming board meeting and trading window closure. The document does not contain any financial data or results itself, nor is it a full report. It is a regulatory announcement related to board activities and compliance with listing obligations. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short (1915 characters), and it is clearly a notice rather than a report or detailed financial disclosure.
2024-11-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of events or information. The document does not contain any financial data, report content, or detailed presentation materials. It is a notification about upcoming meetings rather than the meetings' content or a report. The document length is short (2008 characters), and it serves as an announcement of an event rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-17 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2024. It is addressed to stock exchanges and mentions the enclosure of a certificate from the Registrar and Share Transfer Agent. The document is short (1489 characters) and serves as a compliance certificate rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.